Ceramides and Phosphatidylcholines Associate with Cardiovascular Diseases in the Elderly
Katajamäki et al. Clin Chem. 2022 Dec 6;68(12):1502-1508.
Read morePlasma ceramides independently predict all-cause mortality in men aged 85
Strandberg et al. Age Ageing. 2022 Jun 1;51(6)
Read moreInvitation to the Annual General Meeting
Notice is given to the shareholders of Zora Biosciences Oy of the Annual General Meeting to be held on Thursday, June 30th, 2022 at 10:00…
Read moreInvitation to the Annual General Meeting
Notice is given to the shareholders of Zora Biosciences Oy of the Annual General Meeting to be held on Tuesday, September 28th, 2021 at 11:00…
Read morePrior myocardial infarction, coronary artery disease extent, diabetes mellitus, and CERT2 score for risk stratification in stable coronary artery disease
Hilvo et al. European Journal of Preventive Cardiology. Published 28 August 2021
Read moreComparison of recent ceramide-based coronary risk prediction scores in cardiovascular disease patients
Leiherer et al. European Journal of Preventive Cardiology. Published: 21 August 2021
Read moreAbsolute and relative risk prediction in cardiovascular primary prevention with a modified SCORE chart incorporating ceramide-phospholipid risk score and diabetes mellitus
Hilvo et al. European Heart Journal Open, Published: 13 July 2021
Read morePrimary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts
Hilvo et al. European Journal of Preventive Cardiology, Published 01 June 2021
Read moreA Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
Salminen et al. Cancers 2021, 13(8), 1764.
Read moreZora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test
Zora Biosciences Oy announced it has signed a license agreement with Quest Diagnostics, the world leader in diagnostic information services, for Zora’s patented ceramide-analysis technology.
Read morePlasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome
Gencer et al. 2020 European Journal of Preventive Cardiology. Published online Dec 2020
Read moreCeramides improve atherosclerotic cardiovascular disease risk assessment beyond standard risk factors
Meeusen et al. 2020 Clinica Chimica Acta 511 (2020) 138–142
Read moreCeramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification
Hilvo et al. 2020. Frontiers in Endocrinology. September 2020 | Volume 11 | Article 570628
Read moreAssociations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography
Mantovani et al. 2020 Diabetes & Metabolism, 46(2):150-157.
Read moreZora is part of major European heart disease prevention project
The project is executed together with European Society of Cardiology, ESC, and National Institute for Health and Care Excellence, NICE, as well as cardiologists throughout the Europe.
Read morePrediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy
Hilvo et al. 2020 JAHA, Published Online May 2020
Read moreLDL-Cholesterol Does Not Predict Heart Risk Among Heart Patients
New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory Tests
Read moreDevelopment and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients
Hilvo et al. 2019 Eur Heart J. Published online: 18 June 2019
Read moreZora Biosciences Pushing Ceramide Testing to Assess Cardiovascular Risk
Zora Biosciences is working to expand US and European sales of its ceramide lipid-based cardiovascular risk test, CERT.
Read moreZora Brings Molecular Lipids to the Clinic for Cardiovascular Risk Prediction with Enhanced Capacity
Zora’s laboratory has been able to improve its robotized mass spectrometry workflow such that one machine is able to analyze up to 12 000 samples per…
Read more